Eli Lilly has escalated its legal offensive against compounding pharmacies accused of selling unauthorized copies of its blockbuster diabetes and weight-loss drugs containing tirzepatide, the active ingredient in its high-demand medication, Mounjaro. On Wednesday, the Indianapolis-based pharmaceutical giant announced that it has filed lawsuits against four compounders—Mochi Health Corp, Fella Health and Delilah, Willow Health Services, and Henry Meds—alleging they are manufacturing and distributing unapproved versions of tirzepatide-based products. According to Lilly, these versions are being sold without the clinical evidence required to prove their safety or effectiveness, with some even offered in oral form or mixed with additional ingredients never approved by regulators.